GlobalData Plc
  • Press Release

    Stelara shows excellent efficacy and safety in Crohn’s but its future in the UC market remains uncertain

Following the announcement of positive results from Janssen’s Phase III open label long- term extension study, which evaluates the efficacy and safety data of Stelara in Crohn’s Disease (CD), Patrick Aiyes, Pharma Analyst at GlobalData, a leading data and analytics company, offers his view on Stelara’s future prospects in the Inflammatory Bowel Disease (IBD) market:

“There is clear evidence that Stelara will be a very favorable drug for patients suffering from CD judging by the results. According to GlobalData’s report: ‘Crohn’s Disease’ Stelara will generate blockbuster sales of US$1.3bn in 2026 across the 7MM* in CD, which is around 10% of the total CD market.

“However, in the Ulcerative colitis (UC) market, Stelara is expected to have a slow adoption. Competition in the moderate to severe disease category in UC is expected to intensify over the coming years, making it difficult for Stelara to attain a strong foothold in the UC market.

“Across both the IBD indications, including CD and UC, Stelara is set to generate a total of $1.5bn by 2026.

“It is very important that Janssen positions the drug effectively because the IBD landscape is now becoming a very crowded market place. Janssen currently has nine Phase IV clinical trials in CD for Stelara and has also started to look into Stelara being effective in pediatric and pregnant female populations.”

* 7MM: US, France, Germany, Italy, Spain, UK, Japan.

Related Reports

From GlobalData’s report:

Crohn’s Disease: Dynamic Market Forecast to 2026 Free Sample

Related GlobalData Reports

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF